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ABSTRACT
Application Dengue fever vaccine (CYD-TDV) in Asia currently remains quite limited and
controversial due to safety issues not yet adequately evaluated. Therefore, the purpose of our
review was to assess the safety of the CYD-TDV vaccine based on an analysis of data on its
effectiveness in Asia. A search for relevant keywords in electronic databases found 309
scientific articles, of which only four publications were included in the review. The baseline
serotype prevalence among study participants was 50-80%. With regard to the safety of the
CYD-TDV vaccine, it was shown that reactions at the injection site (pain, edema, erythema)
were noted with a relative risk (RR) of 95% CI (0.46-1.76), and systemic reactions (fever,
headache, myalgia) were also RR 95% CI (0.89-1.81). Of the four papers included in the
review, three contain data on a number of severe adverse effects at RR 95% CI
(0.92-2.11). With regard to immunity, it was shown that for DENV-2 there was a high
geometric mean titer of 67.8 (95% CI 64.8-70.8), DENV-3 - in 73.1 (95% CI 69.9-76.3), and for
DENV-4 - in 65 ( 95% CI 62-67.9), when even lower values ​ ​ are found, this is consistent
with other published work on the immunogenicity of the CYD-TDV vaccine against DENV
serotypes. Our review shows that the CYD-TDV vaccine may be considered for use in Asia, but
subject to a number of conditions and following these safety guidelines. 3), and for DENV-4 - in
65 (95% CI 62-67.9), when, when even smaller values ​ ​ are found, this is consistent with
other published works on the immunogenicity of the CYD-TDV vaccine against DENV
serotypes. Our review shows that the CYD-TDV vaccine may be considered for use in Asia, but
subject to a number of conditions and following these safety guidelines. 3), and for DENV-4 - in
65 (95% CI 62-67.9), when, when even smaller values ​ ​ are found, this is consistent with
other published works on the immunogenicity of the CYD-TDV vaccine against DENV
serotypes. Our review shows that the CYD-TDV vaccine may be considered for use in Asia, but
subject to a number of conditions and following these safety guidelines.
